NFL Week 3 power rankings: Saints and Buccaneers skyrocket, Cowboys and Ravens fall September harvest moon will provide ...

Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

indicating that AbbVie and Lilly are sending a message to government over the issue. The ABPI is concerned that unless addressed, the current situation will result in investment, jobs, and ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.